New antiplatelet agents for cardiovascular disease

descriptionPublicationkeyboard_double_arrow_right Article 09 Sep 2013 English Publisher:CMA Joule Inc.Journal:Canadian Medical Association Journal, volume 185, pages 1,405-1,411 (issn: 0820-3946, eissn: 1488-2329,

Copyright policy )

Authors: Doson, Chua; Cesilia, Nishi;

doi: 10.1503/cmaj.130033

pmid: 24016786

pmc: PMC3826361

New antiplatelet agents for cardiovascular disease

- Summary
- Subjects
- Metrics

Abstract

Antiplatelet therapy is a key component in the management of many medical diseases to decrease the risk of cardiovascular events.[1][1] Acetylsalicyclic acid (ASA) is the most common antiplatelet agent used and is usually first-line therapy. Use of clopidogrel, especially in combination with ASA,

Related Organizations

St. Paul's Hospital
Canada

Keywords

Ticagrelor, Adenosine, Ticlopidine, Pyridines, Coronary Artery Disease, Thiophenes, Piperazines, Clopidogrel, Treatment Outcome, Cardiovascular Diseases, Humans, Prasugrel Hydrochloride, Platelet Aggregation Inhibitors

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	9
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%